FortuneRock Raises $24 Million for Protein Drug Development
October 29, 2014 at 10:06 AM EDT
FortuneRock (China) of Beijing completed a $24 million funding that it will use to advance its portfolio of novel protein drugs. Of the total, $20 million is earmarked for drug development and building a GMP manufacturing facility in Tianjin, which will be spun off into a separate company. The remaining $4 million will underwrite general corporate purposes, including a planned IPO. FortuneRock uses its technology platform to develop novel patent-protected, gene-based recombinant protein drugs that have substantial markets. More details.... Share this with colleagues: // //